Overview
Cannara Biotech Inc., based in Canada, operates primarily in the cannabis industry. The company specializes in the cultivation, processing, and marketing of cannabis and cannabis-derived products within Canadian markets, emphasizing high-quality, value-driven consumer experience in both recreational and medical cannabis sectors. Cannera Biotech leverages advanced agricultural and manufacturing practices at its expansive, state-of-the-art facility located in Quebec, which includes a large-scale indoor cultivation capability. This strategic setup underscores Cannara's focus on innovation and efficiency in production, catering to a demand-centric market. Key projects include increasing its product lineup and market penetration within Canada, ensuring compliance with evolving regulatory frameworks and exploring sustainability initiatives to reduce its environmental footprint in cannabis production.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The revenue for Cannara Biotech Inc. as of May 31, 2025 is 101.87 MM.
- The operating income for Cannara Biotech Inc. as of May 31, 2025 is 21.36 MM.
- The net income for Cannara Biotech Inc. as of May 31, 2025 is 15.52 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2025-05-31 | 101.87 | 21.36 | 15.52 |
| 2025-02-28 | 94.07 | 16.10 | 13.40 |
| 2024-11-30 | 87.28 | 8.37 | 6.64 |
| 2024-08-31 | 81.75 | 7.64 | 6.44 |
| 2024-05-31 | 76.54 | 8.45 | 5.32 |
| 2024-02-29 | 73.26 | 11.54 | 6.22 |
| 2023-11-30 | 66.45 | 14.01 | 9.05 |
| 2023-08-31 | 57.26 | 11.72 | 6.95 |
| 2023-05-31 | 51.07 | 9.73 | 4.87 |
| 2023-02-28 | 44.94 | 6.74 | 3.37 |
| 2022-11-30 | 39.52 | 5.89 | 2.84 |
| 2022-08-31 | 35.84 | 4.82 | 2.31 |
| 2022-05-31 | 30.29 | 2.51 | 0.88 |
| 2022-02-28 | 27.38 | 3.23 | 1.15 |
| 2021-11-30 | 22.22 | 3.24 | 1.44 |
| 2021-08-31 | 17.02 | 0.05 | -1.53 |
| 2021-05-31 | 11.37 | -4.72 | -6.52 |
| 2021-02-28 | 4.98 | -9.26 | -10.59 |
| 2020-11-30 | 3.39 | -12.40 | -13.26 |
| 2020-08-31 | 2.55 | -11.96 | -12.48 |
| 2020-05-31 |
Income Statement: EPS
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2025-05-31 | ||
| 2025-02-28 | ||
| 2024-11-30 | 0.07 | 0.08 |
| 2024-08-31 | 0.07 | 0.07 |
| 2024-05-31 | 0.06 | 0.05 |
| 2024-02-29 | 0.07 | 0.07 |
| 2023-11-30 | 0.10 | 0.10 |
| 2023-08-31 | 0.08 | 0.08 |
| 2023-05-31 | 0.05 | 0.07 |
| 2023-02-28 | 0.04 | 0.04 |
| 2022-11-30 | 0.03 | 0.13 |
| 2022-08-31 | 0.03 | 0.03 |
| 2022-05-31 | 0.01 | -0.01 |
| 2022-02-28 | 0.01 | -0.06 |
| 2021-11-30 | 0.02 | -0.16 |
| 2021-08-31 | -0.02 | -0.10 |
| 2021-05-31 | -0.09 | -0.17 |
| 2021-02-28 | -0.15 | -0.15 |
| 2020-11-30 | -0.18 | -0.18 |
| 2020-08-31 | -0.17 | |
| 2020-05-31 | -0.17 | -0.15 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Cannara Biotech Inc. as of May 31, 2025 is 20.37 MM.
- The cash from investing activities for Cannara Biotech Inc. as of May 31, 2025 is -5.14 MM.
- The cash from financing activities for Cannara Biotech Inc. as of May 31, 2025 is -6.29 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2025-05-31 | 20.37 | -5.14 | -6.29 |
| 2025-02-28 | 10.80 | -3.95 | -4.92 |
| 2024-11-30 | 15.73 | -3.63 | -4.48 |
| 2024-08-31 | 10.68 | -5.19 | -3.14 |
| 2024-05-31 | 10.38 | -6.37 | -2.58 |
| 2024-02-29 | 9.02 | -7.97 | -2.06 |
| 2023-11-30 | 7.01 | -8.47 | -2.65 |
| 2023-08-31 | 5.91 | -9.48 | -4.19 |
| 2023-05-31 | -0.13 | -12.62 | 13.07 |
| 2023-02-28 | -4.81 | -12.89 | 13.73 |
| 2022-11-30 | -6.51 | -15.48 | 14.73 |
| 2022-08-31 | -6.08 | -15.35 | 25.46 |
| 2022-05-31 | -1.53 | -39.62 | 39.56 |
| 2022-02-28 | 1.69 | -37.39 | 39.23 |
| 2021-11-30 | 1.51 | -33.59 | 42.14 |
| 2021-08-31 | -2.09 | -30.83 | 33.25 |
| 2021-05-31 | -5.95 | -2.57 | 2.70 |
| 2021-02-28 | -9.51 | -3.06 | 2.62 |
| 2020-11-30 | -9.43 | -3.64 | 0.11 |
| 2020-08-31 | |||
| 2020-05-31 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2025-05-31 | |||
| 2025-02-28 | |||
| 2024-11-30 | |||
| 2024-08-31 | |||
| 2024-05-31 | |||
| 2024-02-29 | |||
| 2023-11-30 | |||
| 2023-08-31 | |||
| 2023-05-31 | |||
| 2023-02-28 | |||
| 2022-11-30 | |||
| 2022-08-31 | |||
| 2022-05-31 | |||
| 2022-02-28 | |||
| 2021-11-30 | |||
| 2021-08-31 | |||
| 2021-05-31 | |||
| 2021-02-28 | |||
| 2020-11-30 | |||
| 2020-08-31 | |||
| 2020-05-31 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2025-05-31 | ||
| 2025-02-28 | ||
| 2024-11-30 | ||
| 2024-08-31 | ||
| 2024-05-31 | ||
| 2024-02-29 | ||
| 2023-11-30 | ||
| 2023-08-31 | ||
| 2023-05-31 | ||
| 2023-02-28 | ||
| 2022-11-30 | ||
| 2022-08-31 | ||
| 2022-05-31 | ||
| 2022-02-28 | ||
| 2021-11-30 | ||
| 2021-08-31 | ||
| 2021-05-31 | ||
| 2021-02-28 | ||
| 2020-11-30 | ||
| 2020-08-31 | ||
| 2020-05-31 |
Management Effectiveness
- The roa for Cannara Biotech Inc. as of May 31, 2025 is 0.09.
- The roe for Cannara Biotech Inc. as of May 31, 2025 is 0.17.
- The roic for Cannara Biotech Inc. as of May 31, 2025 is 0.09.
- The croic for Cannara Biotech Inc. as of May 31, 2025 is 0.01.
- The ocroic for Cannara Biotech Inc. as of May 31, 2025 is 0.08.
| Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
| 2025-05-31 | 0.09 | 0.17 | 0.09 | 0.01 | 0.08 |
| 2025-02-28 | 0.05 | 0.08 | 0.05 | 0.05 | 0.11 |
| 2024-11-30 | 0.05 | 0.08 | 0.05 | 0.02 | 0.08 |
| 2024-08-31 | 0.04 | 0.07 | 0.04 | 0.01 | 0.08 |
| 2024-05-31 | 0.07 | ||||
| 2024-02-29 | 0.09 | ||||
| 2023-11-30 | 0.13 | 0.11 | -0.05 | ||
| 2023-08-31 | 0.10 | 0.09 | -0.10 | ||
| 2023-05-31 | 0.08 | ||||
| 2023-02-28 | 0.05 | ||||
| 2022-11-30 | 0.00 | ||||
| 2022-08-31 | 0.00 | ||||
| 2022-05-31 | 0.00 | 0.00 | |||
| 2022-02-28 | 0.00 | ||||
| 2021-11-30 | 0.00 | 0.00 | |||
| 2021-08-31 | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 |
| 2021-05-31 | -0.11 | -0.12 | -0.11 | -0.11 | |
| 2021-02-28 | -0.21 | -0.28 | -0.27 | -0.26 | -0.19 |
| 2020-11-30 | -0.21 | -0.28 | -0.27 | -0.26 | -0.19 |
| 2020-08-31 | -0.18 | -0.25 | -0.22 | -0.33 | -0.16 |
| 2020-05-31 | -0.18 | -0.26 | -0.22 | -0.38 | -0.15 |
Gross Margins
- The gross margin for Cannara Biotech Inc. as of May 31, 2025 is 0.42.
- The net margin for Cannara Biotech Inc. as of May 31, 2025 is 0.14.
- The operating margin for Cannara Biotech Inc. as of May 31, 2025 is 0.17.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
| Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
| 2025-05-31 | 0.42 | 0.14 | 0.17 |
| 2025-02-28 | 0.36 | 0.08 | 0.10 |
| 2024-11-30 | 0.36 | 0.08 | 0.09 |
| 2024-08-31 | 0.38 | 0.07 | 0.11 |
| 2024-05-31 | |||
| 2024-02-29 | |||
| 2023-11-30 | 0.14 | 0.21 | |
| 2023-08-31 | 0.12 | 0.20 | |
| 2023-05-31 | 0.10 | 0.19 | |
| 2023-02-28 | 0.07 | 0.15 | |
| 2022-11-30 | |||
| 2022-08-31 | |||
| 2022-05-31 | 0.00 | 0.00 | |
| 2022-02-28 | |||
| 2021-11-30 | |||
| 2021-08-31 | |||
| 2021-05-31 | 0.49 | -0.57 | -0.38 |
| 2021-02-28 | 0.07 | -3.92 | -3.54 |
| 2020-11-30 | 0.07 | -3.92 | -3.54 |
| 2020-08-31 | 0.48 | -4.89 | -4.52 |
| 2020-05-31 | 0.78 | -5.47 | -5.32 |
Identifiers and Descriptors
| Central Index Key (CIK) |
